141 related articles for article (PubMed ID: 16368052)
1. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension.
Narine L; Hague LK; Walker JH; Vicente C; Schilz R; Desjardins O; Einarson TR; Iskedjian M
Curr Med Res Opin; 2005 Dec; 21(12):2007-16. PubMed ID: 16368052
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis.
Einarson TR; Granton JT; Vicente C; Walker J; Engel G; Iskedjian M
Can Respir J; 2005; 12(8):419-25. PubMed ID: 16331313
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
5. Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension.
Reisbig KA; Coffman PA; Floreani AA; Bultsma CJ; Olsen KM
Ann Pharmacother; 2005 Apr; 39(4):739-43. PubMed ID: 15755791
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
[TBL] [Abstract][Full Text] [Related]
7. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
8. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
[TBL] [Abstract][Full Text] [Related]
9. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
Gessler T; Seeger W; Schmehl T
Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
[TBL] [Abstract][Full Text] [Related]
10. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review.
Oudiz RJ; Farber HW
Am Heart J; 2009 Apr; 157(4):625-35. PubMed ID: 19332188
[TBL] [Abstract][Full Text] [Related]
11. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
[TBL] [Abstract][Full Text] [Related]
12. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue.
Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524
[TBL] [Abstract][Full Text] [Related]
13. Advances in prostanoid infusion therapy for pulmonary arterial hypertension.
Doran A; Harris S; Goetz B
J Infus Nurs; 2008; 31(6):336-45. PubMed ID: 19018187
[TBL] [Abstract][Full Text] [Related]
14. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
[TBL] [Abstract][Full Text] [Related]
15. Treatment of pulmonary arterial hypertension: a preliminary decision analysis.
Highland KB; Strange C; Mazur J; Simpson KN
Chest; 2003 Dec; 124(6):2087-92. PubMed ID: 14665484
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
Barst RJ; Galie N; Naeije R; Simonneau G; Jeffs R; Arneson C; Rubin LJ
Eur Respir J; 2006 Dec; 28(6):1195-203. PubMed ID: 16899485
[TBL] [Abstract][Full Text] [Related]
17. Treprostinil for pulmonary hypertension.
Vachiéry JL; Naeije R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
[TBL] [Abstract][Full Text] [Related]
18. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.
Voswinckel R; Enke B; Reichenberger F; Kohstall M; Kreckel A; Krick S; Gall H; Gessler T; Schmehl T; Ghofrani HA; Schermuly RT; Grimminger F; Rubin LJ; Seeger W; Olschewski H
J Am Coll Cardiol; 2006 Oct; 48(8):1672-81. PubMed ID: 17045906
[TBL] [Abstract][Full Text] [Related]
19. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease.
Sakai T; Planinsic RM; Mathier MA; de Vera ME; Venkataramanan R
Transpl Int; 2009 May; 22(5):554-61. PubMed ID: 19175541
[TBL] [Abstract][Full Text] [Related]
20. Treprostinil in advanced experimental pulmonary hypertension: beneficial outcome without reversed pulmonary vascular remodeling.
van Albada ME; van Veghel R; Cromme-Dijkhuis AH; Schoemaker RG; Berger RM
J Cardiovasc Pharmacol; 2006 Nov; 48(5):249-54. PubMed ID: 17110807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]